SKWD:NASDAQSkyward Specialty Insurance Group, Inc. Analysis
Data as of 2026-06-18 - not real-time
$50.51
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Skyward Specialty Insurance Group delivered a **strong first quarter of 2026**, posting revenue of $475.9 million—a 44.8% year‑over‑year increase—and a non‑GAAP profit of $1.25 per share, lifting both earnings and book value. The results were driven by higher managed premiums and the integration of Apollo, signaling an *excellent start* for the combined company. On the technical side, the stock trades at $50.51, comfortably above the 20‑day (46.86), 50‑day (46.17) and 200‑day (46.68) simple moving averages, while the MACD line (1.16) sits above its signal (0.64), indicating bullish momentum. The RSI of 64.9 suggests the stock is approaching overbought territory but remains below the 70 threshold, and price sits near the near‑term resistance of $51.66 with solid support at $42.5. Volatility is elevated at 37% over the past 30 days, yet the beta of 0.32 points to low systematic risk.
Valuation metrics reinforce the upside case: a trailing P/E of 12.2 is well below the industry average of 17.1, and the price‑to‑book ratio of 1.84 reflects a modest premium to net assets. Analysts project a median target of $60, implying roughly 20% upside, while the DCF model suggests a fair value far above the current price, albeit likely optimistic. The company carries no dividend, has a moderate debt‑to‑equity profile (≈40%), and exhibits strong ROE (17%) despite negative free cash flow, which may be temporary due to recent acquisitions. Overall, the blend of solid earnings growth, attractive valuation, low beta, and supportive technical signals underpin a **buy** recommendation across horizons.
Valuation metrics reinforce the upside case: a trailing P/E of 12.2 is well below the industry average of 17.1, and the price‑to‑book ratio of 1.84 reflects a modest premium to net assets. Analysts project a median target of $60, implying roughly 20% upside, while the DCF model suggests a fair value far above the current price, albeit likely optimistic. The company carries no dividend, has a moderate debt‑to‑equity profile (≈40%), and exhibits strong ROE (17%) despite negative free cash flow, which may be temporary due to recent acquisitions. Overall, the blend of solid earnings growth, attractive valuation, low beta, and supportive technical signals underpin a **buy** recommendation across horizons.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD and price above key moving averages
- Strong Q1 earnings and revenue growth
- Support level well below current price with limited downside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued P/E relative to industry peers
- Analyst price target indicating ~20% upside
- Sustained revenue and earnings growth trajectory
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust ROE and solid balance sheet fundamentals
- Low beta indicating defensive characteristics in the insurance sector
- Continued premium expansion and integration benefits from recent acquisition
Key Metrics & Analysis
Financial Health
Revenue Growth44.80%
Profit Margin11.36%
P/E Ratio12.2
ROE17.12%
ROA3.01%
Debt/Equity39.68
P/B Ratio1.8
Op. Cash Flow$427.9M
Free Cash Flow$-261792496
Industry P/E17.1
Technical Analysis
TrendNeutral
RSI64.9
Support$42.50
Resistance$51.66
MA 20$46.86
MA 50$46.17
MA 200$46.68
MACDBullish
VolumeStable
Fear & Greed Index91.18
Valuation
Fair Value$272.38
Target Price$60.64
Upside/Downside20.05%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.32
Volatility37.41%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.